Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $20.83

Shares of Altimmune, Inc. (NASDAQ:ALT) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $20.83.

ALT has been the topic of a number of research analyst reports. William Blair restated a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. Stifel Nicolaus started coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Tuesday, March 18th.

Insider Activity at Altimmune

In other news, CFO Gregory L. Weaver purchased 10,000 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $52,000. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ALT. Ameriprise Financial Inc. lifted its stake in Altimmune by 35.6% in the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock valued at $37,888,000 after purchasing an additional 1,378,854 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after buying an additional 74,194 shares during the last quarter. Bellevue Group AG lifted its position in shares of Altimmune by 9.5% in the fourth quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock valued at $6,817,000 after buying an additional 81,786 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Altimmune by 5.7% during the 4th quarter. Northern Trust Corp now owns 665,916 shares of the company’s stock worth $4,801,000 after acquiring an additional 35,918 shares during the period. Finally, Two Sigma Investments LP increased its holdings in shares of Altimmune by 33.2% during the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock worth $4,364,000 after acquiring an additional 151,001 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Trading Down 2.6 %

NASDAQ:ALT opened at $5.89 on Friday. Altimmune has a 1 year low of $5.14 and a 1 year high of $11.16. The stock has a 50-day moving average price of $6.31 and a two-hundred day moving average price of $7.08. The stock has a market cap of $453.61 million, a price-to-earnings ratio of -3.80 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. Sell-side analysts forecast that Altimmune will post -1.35 earnings per share for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.